1. Home
  2. Clinical Practice
  3. Cardiology
advertisement

ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
  • Overview

    This video brief features Dr. Jung-Sun Kim reporting from AHA 2025 in New Orleans. He highlights the rationale and design of the ADAPT AF-DES trial, which investigates optimal antithrombotic therapy beyond 12 months in patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents (DES). The discussion contextualizes these findings within current guideline recommendations and highlights considerations for individualized therapy.

  • Provider(s)/Educational Partner(s)


    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

Recommended
Details
Presenters
Related
  • Overview

    This video brief features Dr. Jung-Sun Kim reporting from AHA 2025 in New Orleans. He highlights the rationale and design of the ADAPT AF-DES trial, which investigates optimal antithrombotic therapy beyond 12 months in patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents (DES). The discussion contextualizes these findings within current guideline recommendations and highlights considerations for individualized therapy.

  • Provider(s)/Educational Partner(s)


    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free